Abstract:The aim is to observe the expression of human factor VIII gene in mice tranduced in vivo and ex vivo. The vector pLNC-FVIII BD was generated by cloning a B-domain-deleted (760aa-1639aa) FVIII cDNA (FVIIIBD cDNA) into retroviral vector pLNCX. 2 x 10(6) of mouse bone marrow stroma cells transduced by LNC-FVIII BD were infused into 4-week-old BALB/c mice by tail-vein injection. pLNC-FVIII BD was conjugated with PAMAM dendrimer to form complex PAMAM-pLNC-FVIII BD, with which C57BL/6J were injected by tail vein (200 micro l contained 15 micro g/mouse) and sacrificed at days 1, 2, 7, 14, 21 and 28, respectively after injection. Tissue such as liver, spleen, lung and kindney were harvested, with which the transcription were detected by means of RT-PCR. In addition, blood was collected to be measured human FVIII Ag, human FVIIIc and anti-FVIII of human inhibitors. The results showed that the highest level of human FVIII in the recipient BALB/c mice was 8.6 +/- 1.44 ng/ml detected on the first day post-injection; anti-FVIII antibodies were detected from the first week post-injection, and then the level of FVIII Ag decreased and cannot be measured on the fourth week. In the C57BL/6J mice physiological level of human FVIII was expressed in plasma at 48 hours after injection and the average human FVIIIc was 0.62 U/ml and the average human FVIII Ag was 115.5 ng/ml, and gradually reduced later. Anti-FVIII of human inhibitors was not revealed all the time. Syngene image scanning demonstrated that the transcription of the human FVIII BD cDNA occurred mainly in spleen and lung, and secondarily in liver and kidney. No side effects of PAMAM-pLNC-FVIII BD were observed in mice tissue by pathological examination at 4 weeks. In conclusion, retrovirus-transduced bone marrow stroma cells effectively produced human FVIII after ex vivo transduction, but the development of anti-FVIII antibodies in recipient mice influenced the expression level. The human FVIII gene can successfully be transduced in vivo through injecting PAMAM-pLNC-FVIII BD cDNA into mice intravenously. There was physiological level expression of human FVIII in plasma at 48 hours after injection and the average human FVIIIc is 0.62 U/ml and the peak in the six mice was 0.89 U/ml, and gradually reduced later.

Sperm mediated human coagulation factor VIII gene transfer and expression in transgenic mice.

[Sperm-Mediated Expression of Human Clotting Factor VIII Gene in Transgenic Offspring of Mice].

Sustaining Expression of B Domain-Deleted Human Factor VIII Mediated by Using Lentiviral Vectors in NOD/SCID Mouse.

[In Vivo Transfection and Expression of Human Coagulant Factor VIII Cdna in Mice].

[Non-Viral Vector Mediating Human Coagulation Factor VIII Gene Expression in Mouse 32D Cell Line].

Comparison of Human Coagulation Factor VIII Expression Directed by Cytomegalovirus and Mammary Gland-Specific Promoters in HC11 Cells and Transgenic Mice.

Study on the Cloning and Expression of Human Fibrinogen α ,β, γ Gene

Expression of Biologically Active Human Clotting Factor IX (hf IX) in the Mammary Gland of Transgenic Mice

Efficient Stabilization of Recombinant Human Coagulation Factor VIII in the Milk of Transgenic Mice Using Hfviii and Vwf Co-Expression Vector Transduction

High Level Expression of Human Factor VIII in Mammalian Cells after Retroviral-Mediated Gene Transfer.

Efficient Transfer and Expression of Human Clotting Factor IX Cdna in Neonatal Hemophilia B Mice Mediated by VSV-G Pseudotyped Retrovirus

Transgenic Mice Can Express Mutant Human Coagulation Factor IX with Higher Level of Clotting Activity

Expression of Human Clotting Factor Ix Mediated by Recombinant Lentiviral Vector in Cultured Cells and Hemophilia B Mice

Enhancing therapeutic efficacy of in vivo platelet-targeted gene therapy in hemophilia A mice

Characteristics of the Thrombus Formation in Transgenic Mice with Platelet-Targeted Factor VIII Expression

Gene Therapy for Hemophilia B in Immature Mice Using ScAAV-DJ/8-LP1-hFIXco Vector

A high efficient FVIII variant corrects bleeding in hemophilia A mouse model

Gene Delivery of Activated Factor VII Using Alternative Adeno-Associated Virus Serotype Improves Hemostasis in Hemophiliac Mice with FVIII Inhibitors and Adeno-Associated Virus Neutralizing Antibodies.

Expression Of Human Factor Ix Gene In Murine Plasma Through Lentiviral Vector-Infected Haematopoietic Stem Cells

Gene Therapy for Hemophilia B Mediated by Recombinant Adeno-Associated Viral Vector with Hfixr338a,a High Catalytic Activity Mutation of Human Coagulation Factor IX

Ultrasound-mediated gene delivery of factor VIII plasmids for hemophilia A gene therapy in mice